GleamWall
中文EN

EWTX Edgewise Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1710072 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY742.1%
TTM EPS YoY633.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE92.1%
ROA85.4%
ROIC (approx.)-16.6%
Asset turnover—

Leverage & solvency

Liabilities / assets8.3%
Debt / equity0.00x
Current ratio12.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.20x
Accruals ratio102.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$151.39M$126.97M
SG&A expense$40.02M$31.87M
Operating income-$191.41M-$158.83M
Pretax income-$167.80M-$133.80M
Income tax$4,000$3,000
Net income-$167.79M-$133.81M
EBITDA-$189.32M-$156.76M
EPS (basic)-1.63-1.45
EPS (diluted)-1.63-1.45
Weighted avg. shares (diluted)102.93M92.41M
Balance sheet
Cash & equivalents$61.15M$41.67M
Current assets$543.38M$475.48M
PP&E, net$7.83M$9.50M
Total assets$552.60M$486.82M
Current liabilities$27.37M$23.86M
Total liabilities$30.35M$27.60M
Shareholders' equity$522.26M$459.22M
Shares outstanding106.25M94.84M
Cash flow statement
Operating cash flow-$143.82M-$109.03M
Capital expenditure$256,000$1.31M
Free cash flow-$144.07M-$110.34M
Investing cash flow-$32.79M-$184.66M
Financing cash flow$196.09M$249.25M
Depreciation & amortization$2.08M$2.07M
Stock-based compensation$34.75M$24.71M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.